United Therapeutics CorporationUTHR
NasdaqGS•Healthcare•Drug Manufacturers - Specialty & Generic
Analyze revenue and earnings growth — the core drivers of long-term shareholder returns.
TTM revenue reached $3.17B, growing 5.9% year-over-year. TTM net income stood at $1.29B (6.3% growth). Quarterly EBITDA was $348.40M and operating income was $325.80M. Consistent revenue and earnings growth are the primary drivers of long-term shareholder returns. Analyze UTHR growth trends across revenue, EBITDA, operating income, and net income.
Revenue and earnings growth across quarters